Claire Corcoran

University of Liverpool — United Kingdom

Medicine · Health Sciences

20h-index3.5kcitations108works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(29), Advanced Breast Cancer Therapies(26), PARP inhibition in cancer therapy(25), HER2/EGFR in Cancer Research(24), Cancer Genomics and Diagnostics(22)

Publications108 total

Reduction of mandibular doses using noncoplanar VMAT radiotherapy in the adjuvant management of locally advanced oral cavity squamous cell cancers
Medical dosimetry·2025Open Access
Correction: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer
Molecular Cancer·2025Open Access
Editorial Expression of Concern: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer
Molecular Cancer·2024Open Access
Design, synthesis and biological evaluation of a novel bioactive indane scaffold 2-(diphenylmethylene)c-2,3-dihydro-1H-inden-1-one with potential anticancer activity
European Journal of Pharmaceutical Sciences·2023· 7 citedOpen Access
Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
2023Open Access
Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
2023Open Access
Supplementary Data from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
2023Open Access
Data from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
2023· 2 citedOpen Access
Data from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
2023Open Access
Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
2023Open Access
Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
2023Open Access
Supplementary Data from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
2023Open Access
Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
2023Open Access
Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
2023Open Access
Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
2023Open Access
Supplementary Figure from Detection of <i>BRCA1</i>, <i>BRCA2</i>, and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
2023Open Access
Supplementary Material from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i><sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer
2023Open Access
Data from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i><sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer
2023Open Access
Data from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
2023Open Access
Supplementary Data from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Lorraine O’Driscoll(18), Carrie A. Adelman(15), Johann S. de Bono(14), Joaquı́n Mateo(13), David Olmos(13), Sweta Rani(13), Caroline Sibilla(12), Karim Fizazi(11), Fred Saad(11), Neal D. Shore(11), Shahneen Sandhu(11), John Crown(11), Alexander Kohlmann(11), Gaia Schiavon(11), Guilhem Roubaud(10), Mustafa Özgüroğlu(10), Andrew Foxley(10), Justin P.O. Lindemann(10), Rhiannon Maudsley(10), Martin Pass(10)